Utilization of site-specific recombination in biopharmaceutical production

Iranian Biomedical Journal

Volumn 20, Issue 2, 2016, Pages 68-76

  Ahmadi, Maryam ^a,b   Damavandi, Narges ^b,c   Eidgahi, Mohammad Reza Akbari ^a   Davami, Fatemeh ^b  

^a SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

CHO cell; Gene targeting; Site specific recombinase

Indexed keywords

CRE RECOMBINASE; INTEGRASE; LENTIVIRUS VECTOR; PHI C31 INTEGRASE; RECOMBINASE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

BIOENGINEERING; CHROMOSOME ABERRATION; CRISPR CAS SYSTEM; DHFR GENE; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; GENE; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENETIC RECOMBINATION; HUMAN; HUMAN ARTIFICIAL CHROMOSOME; IN VITRO STUDY; LOXP SITE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SITE SPECIFIC RECOMBINATION; TRANSPOSON; ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENETIC ENGINEERING; GENETICS; METABOLISM; PHARMACEUTICS; PROCEDURES;

ANIMALS; BIOPHARMACEUTICS; CHROMOSOMES, ARTIFICIAL, HUMAN; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC ENGINEERING; HUMANS; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC;

EID: 84954451535     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Davami F, Sardari S, Majidzadeh AK, Hemayatkar M, Barkhrdari F, Omidi M, Azami M, Adeli A, Davoudi N, Mahboudi F. Expression of a novel chimeric truncated t- PA in CHO cells based on in silico experiments. The journal of biomedicine and biotechnology 2010; 2010: 08159.
2. Cacciatore JJ, Chasin LA, Leonard EF. Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnology advances 2010; 28(6): 673-681.
3. Wirth D, Gama-Norton L, Riemer P, Sandhu U, Schucht R, Hauser H. Road to precision: recombinase-based targeting technologies for genome engineering. Current opinion in biotechnology 2007; 18(5): 411-419.
4. Turan S, Galla M, Emst E, Qiao J, Voelkel C, Schiedlmeier B, Zehe C, Bode J. Recombinasemediated cassette exchange (RMCE): traditional concepts and current challenges. Journal of molecular biology 2011; 407(2): 193-221.
5. Zhu J, Park CW, Sjeklocha L, Kren BT, Steer CJ. Highlevel genomic integration, epigenetic changes and expression of sleeping beauty transgene. Biochemistry 2010; 49(7): 1507-1521.
6. Voziyanov Y, Konieczka JH, Stewart AF, Jayaram M. Stepwise manipulation of DNA specificity in Flp recombinase: progressively adapting Flp to individual and combinatorial mutations in its target site. The journal of molecular biology 2003; 326(1): 65-76.
7. Santoro SW, Schultz PG. Directed evolution of the site specificity of cre recombinase. Proceeding of the national of academy sciences of the United States of America 2002; 99(7): 4185-4190.
8. Bode J, Schlake T, Iber M, Schübeler D, Seibler J, Snezhkov E, Nikolaev L. The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes. Biological chemistry 2000; 381(9- 10):801-813.
9. Muñ oz-Ló pez M, García-Pérez JL. DNA transposons: nature and applications in genomics. Current genomics 2010; 11(2): 115-128.
10. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005; 122(3):473-483.
11. Mitra R, Fain-Thornton J, Craig N L. PiggyBac can bypass DNA synthesis during cut and paste transposition. The EMBO journal 2008; 27(7): 1097- 1109.
12. Yant SR, Huang Y, Akache B, Kay MA. Site-directed transposon integration in human cells. Nucleic acids research 2007; 35(7): e50.
13. Balciunas D, Wangensteen KJ, Wilber A, Bell J, Geurts A, Sivasubbu S, Wang X, Hackett PB, Mclvor RS, Ekker SC. Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS genetics 2006; 2(11): e169.
14. Wu SC, Meir YJ, Coates CJ, Handler AM, Pelczar P, Moisyadi S, Kaminski JM. PiggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2 and Mos1 in mammalian cells. Proceeding of the national academy of sciences of the United States of America 2006; 103(41): 15008-15013.
15. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH. Hyperactive piggyBac gene transfer in human cells and in vivo. Human gene therapy 2012; 23(3): 311-20.
16. Ivana Grabundzija, Markus Irgang, Lajos Mátés, Eyayu Belay, Janka Matrai, Andreas Gogol-Dö ring, Koichi Kawakami, Wei Chen, Patricia Ruiz, Marinee K. L. Chuah, Thierry VandenDriessche, Zsuzsanna Izsvák, Zoltán Ivics. Comparative analysis of transposable element vector systems in human cells. Molecular therapy 2010; 18(6): 1200-1209.
17. Mates L, Izsvak Z, Ivics Z. Technology transfer from worms and flies to vertebrates: transposition -based genome manipulations and their future perspectives. Genome biology 2007; 8(supp1): S1.
18. Balasubramanian S, Matasci M, Kadlecova Z, Baldi L, Hacker DL, Wurm FM. Rapid recombinant protein production from piggyBac transposon-mediated stable CHO cell pools. The journal of biotechnology 2015; 200: 61-69.
19. Matasci M, Baldi L, Hacker DL, Wurm FM. The piggyBac transposon enhances the frequency of CHO stable cell line generation and yields recombinant lines with superior productivity and stability. Biotechnology and bioengineering 2011; 108(9): 2141-2150.
20. Barron N, Piskareva O, Muniyappa M. Targeted genetic modification of cell lines for recombinant protein production. Cytotechnology 2007; 53(1-3): 65-73.
21. Matasci M, Bachmann V, Baldi L, Hacker DL, De Jesus M, Wurm FM. CHO cell lines generated by piggyBac transposition. BMC proceedings 2011; 5(Suppl 8): 31.
22. Kito M, Itami S, Fukano Y, Yamana K, Shibui T. Construction of engineered CHO strains for high-level production of recombinant proteins. Applied microbiology and biotechnology 2002; 60(4): 442-448.
23. Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer research 1989; 49(7): 1738-1745.
24. Zhou H, Liu ZG, Sun ZW, Yu WY. Development of site-specific integration system to high-level expression recombinant proteins in CHO cells. Chinese journal of biotechnology 2007; 23(4): 756-762.
25. Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Molecular and cellular biology 2001; 21(12): 3926- 3934.
26. Huang Y, Li Y, Wang YG, Gu X, Wang Y, Shen BF. An efficient and targeted gene integration system for high-level antibody expression. Journal of immunological methods 2007; 322(1-2): 28-39.
27. Thyagarajan B, Calos MP. Site-specific integration for high-level protein production in mammalian cells. Methods in molecular biology 2005; 308: 99-106.
28. Geisinger JM, Calos MP. Site-specific recombination using PhiC31 integrase. Springer 2013; 23: 211-239
29. Larin Z, Mejia JE. Advances in human artificial chromosome technology. Trends in genetics 2002; 18(6): 313-319.
30. Basu J, Willard HF. Human artificial chromosomes: Potential applications and clinical considerations. Pediatric clinics of North America 2006; 53(5): 843- 853.
31. Kennard, ML. Engineered mammalian chromosomes in cellular protein production: future prospects. Methods in molecular biology 2011; 738: 217-238.
32. Kennard ML, Goosney DL, Monteith D, Zhang L, Moffat M, Fischer D, Mott J. The generation of stable, high MAb expressing CHO cell lines based on the artificial chromosome expression (ACE) technology. Biotechnology and bioengineering 2009; 104(3): 540- 553.
33. Dejong G, Telenius AH, Telenius H, Perez CF, Drayer JI, Hadlaczky G. Mammalian artificial chromosome pilot production facility: Large-scale isolation of functional satellite DNA-based artificial chromosomes. Cytometry 1999; 35(2): 129-133.
34. Yamaguchi S, Kazuki Y, Nakayama Y, Nanba E, Oshimura M, Ohbayashi T. A method for producing transgenic cells using a multi-Integrase system on a human artificial chromosome vector. PLoS one 2011; 24(6): e17267.
35. Miskey C, Izsvak Z, Kawakami K, Ivics Z. DNA transposons in vertebrate functional genomics. Cellular and molecular life sciences 2005; 62(6): 629-641.
36. Ivics Z, Katzer A, Stüwe EE, Fiedler D, Knespel S, Izsvák Z. Targeted sleeping beauty transposition in human cells. Molecular therapy 2007; 15(6): 1137- 1144.
37. Wilson MH, Coates CJ, George LJ. PiggyBac transposon-mediated gene transfer in human cells. Molecular therapy 2007; 15(1): 139-145.
38. Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nature methods 2009; 6(5): 363-369.
39. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM, Kohn DB. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells using the sleeping beauty transposon system. Human gene therapy 2009; 20(12): 1607-1626.
40. Xue X, Huang X, Nodland SE, Mátés L, Ma L, Izsvák Z, Lebien TW, Mcivor RS, Wagner JE, Zhou Z. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive sleeping beauty transposon system. Blood 2009; 114(7): 1319-1330.
41. Branda CS, Dymecki SM. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Developmental cell 2004; 6(1):7-28.
42. Glaser S, Anastassiadis K, Stewart AF. Current issues in mouse genome engineering. Nature genetics 2005; 37(11): 1187-1193.
43. Liu Y, Lakshmipathy U, Ozgenc A, Thyagarajan B, Lieu P, Fontes A, Xue H, Scheyhing K, MacArthur C, Chesnut JD. hESC engineering by integrase-mediated chromosomal targeting. Methods in molecular biology 2010; 584: 229-268.
44. Ehrhardt A, Engler JA, Xu H, Cherry AM, Kay MA. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Human gene therapy 2006; 17(11): 1077-1094.
45. Lim F, Palomo GM, Mauritz C, Giménez-Cassina A, Illana B, Wandosell F, wandosell F, Nido J. "Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Molecular therapy 2007; 15(6): 1072-1078.
46. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer selfinactivating lentiviral vectors. Molecular therapy 2001; 3(1): 97-104.
47. Sadaie MR, Arya SK. HIV-derived lentiviral vectors: current progress toward gene therapy and DNA vaccination. Iranian Biomedical Journal 1998; 2(4-3): 95-103
48. Gaillet B, Gilbert R, Broussau S, Pilotte A, Malenfant F, Mullick A, Massie B. High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch. Biotechnology and bioengineering 2010; 106(2): 203-215.
49. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, Doering CB. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Molecular therapy 2011; 19(2): 302-309.
50. Oberbek A, Matasci M, Hacker DL, Wurm FM. Generation of stable, high-producing cho cell lines by lentiviral vector-mediated gene transfer in serum-free suspension culture. Biotechnology and bioengineering 2011; 108(3): 600-610.
51. Katz RA, Merkel G, Skalka AM. Targeting of retroviral integrase by fusion to a heterologous DNA binding domain: in vitro activities and incorporation of a fusion protein into viral particles. Virology 1996; 217(1): 178- 190.
52. Tan W, Zhu K, Segal DJ, Barbas CF, Chow SA. Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. Journal of virology 2004; 78(3): 1301-1313.
53. Lombardo A, Calos M, Naldini L. Development of a new lentiviral vector for site-specific integration into mammalian genomes. Molecular therapy 2005; 11: 152.
54. Desfarges S, Ciuffi A. Retroviral integration site selection. Viruses 2010; 2(1): 111-130.
55. Gaj T, Gersbach CA, Barbas CF. ZFN, ALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology 2013; 31(7): 397-405.
56. Sealover NR, Davis AM, Brooks JK, George, HJ, Kayser KJ, Lin N. Engineering Chinese Hamster Ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)- mediated gene knockout of mannosyl (alpha-1, 3-)- glycoprotein beta-1, 2-N-acetylglucosaminyltransferase (Mgat1). The journal of biotechnology 2013; 167(1): 24- 32.
57. Ho SC, Tong YW, Yang Y. Generation of monoclonal antibody-producing mammalian cell lines. Pharmaceutical bioprocessing 2013; 1(1): 71-87.
58. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Zhang F, Marraffini LA, Jiang W, Wu X, Hsul P. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339(6121): 819-823.
59. Ronda C, Pedersen LE, Hansen HG, Kallehauge TB, Betenbaugh MJ, Nielsen AT, Kildegaard HF. Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnology and bioengineering 2014; 111(8): 1604-1616.
60. Lee JS, Grav LM, Lewis NE, Kildegaard HF. CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives. Biotechnology journal 2015; 10(7): 979-994.
61. Lee JS, Kallehauge TB, Pedersen LE, Kildegaard HF. Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Scientific reports 2015; 5: 8572.
62. Davami F, Barkhordari F, Alebouyeh M, Adeli A, Mahboudi F. Combined TGE-SGE expression of novel PAI-1-resistant t-PA in CHO DG44 cells using orbitally shaking disposable bioreactors. The journal of microbiology and biotechnology 2011; 21(12): 1299- 1305.
63. Ivana Grabundzija, Markus Irgang, Lajos Mátés, Eyayu Belay, Janka Matrai, Andreas Gogol-Dö ring. Comparative analysis of transposable element vector systems in human cells. Molecular therapy 2010; 18(6) 1200-1209.
64. Davami F, Eghbalpour F , Nematolla L, Barkhordari F, Mahboudi F. Effects of peptone supplementation in different culture media on growth, metabolic pathway and productivity of CHO DG44 cells; a new insight into amino acid profiles. Iranian biomedical journal 2015; 19(4): 194-205.
65. Davami F, Sardari S, Majidzadeh AK, Hemayatkar M, Barkhordari F, Enayati S, Adeli A, Mahboudi F. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments. BMB reports 2011; 44(1): 34-39.
66. Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnology advances 2012; 30(5): 1158-1170.
67. Groth AC, Calos MP. Phage integrases: biology and applications. Journal of molecular biology 2004; 335(3): 667-678.
68. Ehrhardt A, Engler JA, Xu H, Cherry AM, Kay MA. Molecular analysis of chromosomal rearrangements in mammalian cells after ø C31-mediated integration. Human gene therapy 2006; 17(11): 1077-1094.
69. Macnab S, Whitehouse A. Progress and prospects: human artificial chromosomes. Gene therapy 2009; 16(10): 1180-1188.
70. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS. Analysis of off-target effects of CRISPR/Casderived RNA-guided endonucleases and nickases. Genome research 2014; 24(1): 132-141.